Clinical trial NCT00784615 - References

Polycystic Ovary Syndrome — Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome

Citation(s)

•   Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group
  The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.
•   Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF
  A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000 Jul;85(7):2434-8.
•   Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO
  The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9.
•   Azziz R
  Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006 Mar;91(3):781-5. Epub 2006 Jan 17.
•   Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ
  Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986 May;62(5):904-10.
•   Bloomgarden ZT
  American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003 Apr;26(4):1297-303. Review.
•   Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z
  Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004 May;89(5):2160-5.
•   Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA
  Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.
•   Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A
  Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604.
•   Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI
  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999 Nov;84(11):4006-11.
•   Dunaif A, Segal KR, Futterweit W, Dobrjansky A
  Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989 Sep;38(9):1165-74.
•   Dunaif A
  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. Review.
•   Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J
  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan;22(1):141-6.
•   Ehrmann DA
  Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24;352(12):1223-36. Review.
•   Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97.
•   FERRIMAN D, GALLWEY JD
  Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 Nov;21:1440-7.
•   Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M
  The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997 Dec;12(12):2641-8. Review.
•   Franks S
  Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006 Mar;91(3):786-9. Epub 2006 Jan 17. Review.
•   Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N
  Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001 Jun;86(6):2453-5.
•   Kershaw EE, Flier JS
  Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56. Review.
•   Legro RS, Kunselman AR, Dunaif A
  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001 Dec 1;111(8):607-13.
•   Legro RS
  Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003 Jun;24(3):302-12. Review.
•   Legro RS
  The genetics of polycystic ovary syndrome. Am J Med. 1995 Jan 16;98(1A):9S-16S. Review.
•   Ludwig E
  Androgenetic alopecia. Arch Dermatol. 1977 Jan;113(1):109.
•   Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG
  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991 Jan;72(1):83-9.
•   Norman RJ, Homan G, Moran L, Noakes M
  Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine. 2006 Aug;30(1):35-43. Review.
•   Orio F Jr, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R
  Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2619-23.
•   Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y
  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999 Dec 21-28;100(25):2473-6.
•   Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD
  Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001 Mar 13;103(10):1410-5.
•   Ridker PM, Buring JE, Cook NR, Rifai N
  C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003 Jan 28;107(3):391-7.
•   Ridker PM, Rifai N, Rose L, Buring JE, Cook NR
  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
•   Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S
  Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996 Mar;44(3):277-84.
•   Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.
•   Sam S, Dunaif A
  Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003 Oct;14(8):365-70. Review.
•   Sir-Petermann T, Maliqueo M, Codner E, Echiburú B, Crisosto N, Pérez V, Pérez-Bravo F, Cassorla F
  Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Dec;92(12):4637-42. Epub 2007 Sep 11.
•   Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA
  Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22.
•   Wild RA
  Long-term health consequences of PCOS. Hum Reprod Update. 2002 May-Jun;8(3):231-41. Review.

Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome

Details for clinical trial NCT00784615